{"id":"W4406665590","doi":"10.1158/1078-0432.ccr-24-3128","title":"Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech","keywords":"Medicine; Internal medicine; Bevacizumab; Neutropenia; Ovarian cancer; Clinical endpoint; Paclitaxel; Oncology; Refractory (planetary science); Progression-free survival; Phases of clinical research; Mesothelin; Gastroenterology; Urology; Cancer; Randomized controlled trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001705546,0.001383442,0.00180959,0.0003604068,0.0003621776,0.0009751934,0.0009272595,0.001197607,0.00560032],"category_scores_gemma":[0.001371082,0.0005989556,0.000886681,0.0002999845,0.0007641012,0.0006471592,0.0003641475,0.002853995,0.0008494087],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001052144,"about_ca_system_score_gemma":0.001361917,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001809844,"about_ca_topic_score_gemma":0.004935104,"domain_scores_codex":[0.9994961,0.000307565,0.00002120113,0.00007587826,0.00003282255,0.0000664605],"domain_scores_gemma":[0.9991387,0.00015158,0.0002021552,0.00008502097,0.00004464028,0.0003778409],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9523493,0.01630173,0.001365284,0.000258763,0.0007078418,0.00005988665,0.0000665829,0.0006989241,0.007418002,0.0001559964,0.001882776,0.01873491],"study_design_scores_gemma":[0.927565,0.06751715,0.002350725,0.00001257856,0.0002462507,0.00005109833,0.0000145713,0.000556501,0.000635831,0.0001200922,0.0009198936,0.00001044111],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990876,0.001466799,0.0005146961,0.0006219007,0.0003050547,0.0030262,0.001158036,0.0001267429,0.00190464],"genre_scores_gemma":[0.9870281,0.001116809,0.001578096,0.0009419688,0.0002744384,0.003321676,0.002043374,0.00003656258,0.003659081],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00560032,"threshold_uncertainty_score":0.01873499,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1889745622034815,"score_gpt":0.5220860365257134,"score_spread":0.3331114743222319,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}